In this interview from the MedTech Unplugged series at the New York Stock Exchange, Kevin Reilly, managing director and head of med tech at Ally Bridge Group, joins theCUBE’s John Furrier to offer a private equity perspective on the fast-evolving MedTech landscape. Reilly shares how Ally Bridge is deploying over $1.5 billion in capital across life sciences and MedTech, targeting best-in-class and first-in-class technologies across cardiovascular, neurovascular, robotics and diagnostics.
The conversation dives into how AI-enabled devices like wearable defibrillators and seizure-monitoring headsets are transforming patient care and lowering costs by catching disease earlier. Reilly explains why Ally Bridge invests in FDA-cleared companies and helps them scale by navigating complex regulatory, physician adoption and reimbursement pathways. He also weighs in on the thawing IPO market after a multi-year freeze, highlighting recent exits like Kestra and Cervella and predicting a strong pipeline of high-growth MedTech firms entering public markets.
With AI, supercomputing and structural shifts in healthcare delivery reshaping the MedTech landscape, Reilly underscores the importance of clinical data, patient-centric outcomes and strategic capital deployment in driving the next wave of innovation.
Watch the interview